antihaemophilic factor + porcine factor viii:c + susoctocog alfa at a glance
Medicine class
Recombinant blood coagulation factor VIII.
Licensed use
Bleeding episodes in adults with acquired haemophilia caused by factor VIII antibodies.
Administration
Given intravenously in hospital under specialist supervision.
Monitoring
Bleeding response and factor VIII activity are monitored because individual responses vary.
What is antihaemophilic factor + porcine factor viii:c + susoctocog alfa used for?
The selected product is licensed for:
Treatment of bleeding episodes in adults with acquired haemophilia caused by antibodies against factor VIII.
How does antihaemophilic factor + porcine factor viii:c + susoctocog alfa work?
Factor VIII works with activated factor IX to generate activated factor X, thrombin and ultimately fibrin, which stabilises a blood clot. In acquired haemophilia, antibodies neutralise human factor VIII; they generally have less cross-reactivity with this porcine-sequence factor VIII, allowing temporary replacement of clotting activity.
How to take antihaemophilic factor + porcine factor viii:c + susoctocog alfa
This treatment is prepared and given intravenously by trained hospital staff under a haemophilia specialist's supervision.
The powder is reconstituted with the supplied water for injections using aseptic technique.
The prepared solution should be clear and colourless; it must not be used if discoloured or containing particles.
It should not be mixed with other injectable medicines in the same container or tubing.
The product name and batch number should be recorded for traceability.
antihaemophilic factor + porcine factor viii:c + susoctocog alfa side effects
Common or expected effects
- An anamnestic response—an increase in existing human or porcine factor VIII inhibitors—is very common and may reduce effectiveness.
- A positive test for inhibitory antibodies against porcine factor VIII is common.
Get urgent medical advice
- Severe hypersensitivity or anaphylaxis, potentially involving hives, swelling, wheezing, low blood pressure or shock.
- Loss of effectiveness caused by inhibitory antibodies, presenting clinically as bleeding that does not improve.
- High, sustained factor VIII activity may increase thromboembolic risk, particularly in older people or those with cardiovascular disease.
antihaemophilic factor + porcine factor viii:c + susoctocog alfa in pregnancy
There is no established experience of use during pregnancy and animal reproductive studies have not been conducted. It should be used only when a specialist considers it clearly indicated.
antihaemophilic factor + porcine factor viii:c + susoctocog alfa while breastfeeding
Experience during breastfeeding is unavailable. Use should be limited to situations where the specialist considers treatment clearly indicated.
antihaemophilic factor + porcine factor viii:c + susoctocog alfa interactions
No interactions with other medicines have been reported, but the evidence base is limited.
Other medicines, including haemostatic treatments
Give the specialist a complete current medicines list so combined treatment and bleeding or clotting risks can be assessed.
Common questions about antihaemophilic factor + porcine factor viii:c + susoctocog alfa
Answers are fully visible for fast scanning and source review.
What is antihaemophilic factor + porcine factor viii:c + susoctocog alfa used for?
It treats active bleeding episodes in adults with acquired haemophilia caused by antibodies against factor VIII.
Is antihaemophilic factor + porcine factor viii:c + susoctocog alfa used for inherited haemophilia A?
The selected product is not licensed for inherited haemophilia A and is contraindicated in congenital haemophilia A with inhibitors.
Why does antihaemophilic factor + porcine factor viii:c + susoctocog alfa use porcine-sequence factor VIII?
Antibodies against human factor VIII often have less effect on porcine-sequence factor VIII, allowing it to provide temporary clotting activity.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.